Navigation Links
High Intensity Focused Ultrasound for Locally Recurrent Prostate Cancer Following External Beam Radiation Therapy Investigated in Phase III Clinical Study
Date:9/11/2008

CHARLOTTE, N.C., Sept. 11 /PRNewswire/ -- In a new study, men with locally recurrent prostate cancer may be able to receive a promising investigational ultrasound treatment option.

A Phase III clinical trial at Specialists in Urology, located in North Naples, FL, is investigating the safety and efficacy of High Intensity Focused Ultrasound (HIFU) for the treatment of locally recurrent prostate cancer following failed external beam radiation therapy (EBRT). HIFU is a minimally invasive procedure that uses ultrasound energy to destroy cancerous tissue with focused sound waves.

The lead investigator of this trial site is Dr. Nicholas Franco. This is one of several trial sites in the nation approved by the Food and Drug Administration to participate in the trial, which will begin enrolling patients in September.

HIFU is intended to eliminate cancer by elevating tissue temperatures to more than 195 degrees Fahrenheit in a matter of seconds. The Sonablate(R) 500, the therapeutic ultrasound device, which will be used in the study, is designed to destroy the entire gland in one procedure without causing damage to tissue around the prostate.

Eligible participants for the trial must be between the ages of 40 and 80, have biopsy confirmed local recurrence two or more years following EBRT, confined prostate cancer with a prostate specific antigen (PSA) greater than or equal to .5 ng/mL and less than or equal to 10 ng/mL and a Gleason score of less than or equal to seven.

For more information about enrolling in the HIFU trial, call 1-877-874-4389, or visit http://www.ProstateCancerRecurrentTrial.org.

This investigational treatment is performed on an outpatient basis. Potential risks of the treatment include frequency, urgency, mild discomfort or discharge in urinary stream. Less common side effects may also include urinary stricture, retention, incontinence, i
'/>"/>

SOURCE USHIFU
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Nations Foremost Health Care Leaders Kick Off Summit Focused on Zero-Tolerance Approach to Hospital-Acquired Infections
2. Rosetta Genomics and Rabin Medical Center Announce a Collaboration Focused on MicroRNA-Based Diagnostics
3. ACORNs Oncology-focused Contract Research Organization Exceeds Projections
4. Applisonix Announces Breakthrough in Ultrasound Technology for Hair Removal - Average Hair Reduction of 38% Following Initial Treatment
5. Adding Breast Ultrasound Screening to Mammography Reveals Cancers not Seen on Mammography Alone in Women at Increased Risk for Breast Cancer
6. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
7. Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery
8. Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel
9. Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events
10. Current Concepts in Clostridium difficile Infection: A Focus on Recurrent Disease
11. Leading Academic Institutions Collaborate on 800-Patient Study of Effectiveness of Cryoablation for Men With Recurrent Prostate Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...a-FirstCall/--ChinaSkyOne,Medical,Inc.("ChinaSkyOn...ullyintegratedpharmaceuticalcompanydevelopingandpr...ofChina("PRC"),today,announcedthattheCompanyrecent...fPharmaceuticalandBiologicalProducts("ICPBP")exami...umanProstateSpecific,Antigen(ColloidalGold)anditsD...
(Date:11/25/2009)...AccordingtoMillenniumResearchGroup(MRG),theglobala...early$3billionUSmarketfortraumafixationdeviceswill...etherecenteconomicslowdown.MRG,s USMarketsforTraum...highlydynamicoverthenextfiveyears,withcompetitorsi...dsegmentsofthetraumafixationmarket,fuelingmarketgr...
(Date:11/25/2009)...G,November25/PRNewswire/--,iThembaPharmaceuticals,...ttheyhavesignedacollaborativeagreementtojointlymar...sscomputationalchemistryandleaddiscoveryexpertise,...medicinaland,syntheticchemistrysupporttoprojectsid...ThembaPharmaceuticalsandPyxisDiscovery,alsoannounc...
Breaking Medicine Technology:China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 2China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 3US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2AUDIO from Medialink and Guardian 3A Breast Cancer Awareness Month Highlights Need for Critical Illness Insurance 59684 1International SOS Awarded TRICARE Overseas Program Contract 59681 1International SOS Awarded TRICARE Overseas Program Contract 59681 2FDA Approves Elitek 28R 29 28rasburicase 29 for Management of Plasma Uric Acid Levels in Adults with Leukemia Lymphoma and Solid Tumors Receiving A 5545 1FDA Approves Elitek 28R 29 28rasburicase 29 for Management of Plasma Uric Acid Levels in Adults with Leukemia Lymphoma and Solid Tumors Receiving A 5545 2FDA Approves Elitek 28R 29 28rasburicase 29 for Management of Plasma Uric Acid Levels in Adults with Leukemia Lymphoma and Solid Tumors Receiving A 5545 3FDA Approves Elitek 28R 29 28rasburicase 29 for Management of Plasma Uric Acid Levels in Adults with Leukemia Lymphoma and Solid Tumors Receiving A 5545 4FDA Approves Elitek 28R 29 28rasburicase 29 for Management of Plasma Uric Acid Levels in Adults with Leukemia Lymphoma and Solid Tumors Receiving A 5545 5FDA Approves Elitek 28R 29 28rasburicase 29 for Management of Plasma Uric Acid Levels in Adults with Leukemia Lymphoma and Solid Tumors Receiving A 5545 6FDA Approves Elitek 28R 29 28rasburicase 29 for Management of Plasma Uric Acid Levels in Adults with Leukemia Lymphoma and Solid Tumors Receiving A 5545 7
...IRE)--Jun 13, 2007 - EPIX,Pharmaceuticals, Inc. (N...ase 3 trial of PRX-00023, a novel long-acting 5-HT...at the 47th Annual New,Clinical Drug Evaluation Un...ting is sponsored by the National Institutes of,He...armacology., The presentation highlighted data fro...
..., WA -- (MARKET WIRE) -- June 14,2007 -- Targeted...rting data from the dose escalation arm of the ong...nts with inflammatory,arthritis. Philip J. Mease, ...ington School of Medicine, chief of rheumatology,c...acticing,physician with Seattle Rheumatology Assoc...
Other Medicine Technology:EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 2EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 3EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 4Targeted Genetics Reports Inflammatory Arthritis Clinical Data at,European Rheumatology Conference 2Targeted Genetics Reports Inflammatory Arthritis Clinical Data at,European Rheumatology Conference 3Targeted Genetics Reports Inflammatory Arthritis Clinical Data at,European Rheumatology Conference 4Targeted Genetics Reports Inflammatory Arthritis Clinical Data at,European Rheumatology Conference 5Targeted Genetics Reports Inflammatory Arthritis Clinical Data at,European Rheumatology Conference 6
(Date:11/26/2009)...ers from the North Pole, Textsanta.net lets parent...a , North Pole, AK (PRWEB...cies at the North Pole Santa Claus has added SMS t...lobe informed of his Christmas progress at the Nor...tment have identified a large and growing percenta...
(Date:11/26/2009)...Ennis, P.A. is offering free nationwide confidenti... control pills who have suffered a Deep Vein Throm...ack or other related cardiac issues or had their G...800-856-6405 or go to the firm’s website at ...ase evaluation form. , (P...
(Date:11/25/2009)...swire/-SentinelleMedicalInc.,aleadingmanufacturero...algaryScientificInc.,aleadingproviderofsoftwareena...(TM)Breast4DAdvancedVisualizationsoftware. ,, T...tWebclientbasedmedicalimagingofferinginthemarket.C...-footprintaccess-requiringnosoftwaredownload,andru...
(Date:11/25/2009)...SNewswire/--TheBlackAIDSInstituterecentlyheldBoard...or2010. ,, ThenewBoardMembersareahighlydiverseg...ance,governmenthealthprograms,editorial,andbusines...fpersonalbackgroundsincludingbothheterosexualandga...epresentingmultipleagegroups. ,, (Photo: http:/...
(Date:11/25/2009)... statistically significant survival benefit from a...ceptor (ER)-positive tumors had high levels of pho...S118-P), according to a brief communication publis...onal Cancer Institute . , Approximately 50% of b...inical studies have shown that ER-alpha S118-P is ...
Breaking Medicine News(10 mins):Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 3Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 3Health News:Black AIDS Institute Announces 2010 Board Election Results 2
... human welfare, spread of infectious disease and f...atellite imagery in order to acquire the proper ba...in, the geography professor of Kansas State Univer... Doug Goodin uses remote sensing, in combinati...
...ate University, Doug Goodin, makes use of satellit...and cover //changes on human health and food secur...with other types of data, to monitor and predict t... Decisions about Human Welfare," which was sponsor...
... have been able to zero in (on) the modalities of ... and other types of diseases. // Clinical trials o...drug to reduce the potency of a key enzyme, in cha...nn Collegiate Professor of Chemistry at U-M. 'Ou...
...ecialist, NHS can be freed from its’ problems, if ..., are reconsidered before they are implemented. //...vatization plan may make matters worse for the dep...ce has deteriorated. Though plans of privatization...
... the launch of BARACLUDE? (entecavir) for the tre...llowing its approval by the Drug Controller Genera...ed for the treatment of chronic hepatitis B virus ...histologically active disease. BARACLUDE? is...
... are repeatedly failing to implement rules that wi...atients //from contaminated surgical instruments. ...keeping instruments in sets so they can be traced ...to see that surgical instruments were not contamin...
Other Medicine News:Health News:Ecological Changes affects human health, food security 2Health News:Satellite Imagery to monitor the Social Impact Of Geographical Changes 2Health News:Autoimmune disorders studied in detail by U-M researchers. 2Health News:India Approves Baraclude? (entecavir) For ,Treatment Of Chronic HEPATITIS B 2
Anti-MPO - ELISA (P-ANCA)
Myeloperoxidase (MPO) Enzyme-Linked Immunosorbent Assay (ELISA)
Iso-Insulin ELISA
RIDASCREEN Anti-RSV IgM Assay
Medicine Products: